New research suggests eliminating senescent cells may enhance breast and pancreatic cancer treatment by enhancing immune response.
- Senescent cells have been identified in breast and pancreatic tumors, driving inflammation and suppressing the immune system, allowing tumor growth.
- Research led by Sheila A. Stewart and David G. DeNardo suggests that targeting specific senescent cells in tumors through senolytic therapy could enhance the effectiveness of immunotherapies and chemotherapies.
- In mice models, eliminating senescent cells in breast cancer activated natural killer cells and other anti-tumor immune functions, suppressing tumor growth.
- Similarly, in pancreatic cancer, removing senescent cells increased the activity of killer T cells and other anti-cancer immune functions, restricting tumor growth.
- The findings highlight the potential for senolytic therapy to be incorporated into breast and pancreatic cancer treatment regimens to improve patient outcomes.
Source link
Oncology